NCT03242083
Completed
Not Applicable
Evaluation de la Quality of Life in Secondary Atrophic Age-related Macular Degeneration
ConditionsAge-related Macular Degeneration
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Age-related Macular Degeneration
- Sponsor
- Centre Hospitalier Universitaire Dijon
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- responses to a quality of life questionnaire
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Age-related macular degeneration (AMD) is a major cause of deep visual acuity loss. Because of progressive deterioration of the macula, patients with AMD complain about progressive visual problems that can impair their quality of life in the physical, mental and social domains. The principal objective principal of this study is to describe the evolution of quality of life between the diagnosis of secondary atrophic AMD and at 18 months after confirmation of diagnosis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For the 2 populations studied
- •Persons who have given consent to take part
- •Persons aged 50 years or older
- •Willing and able to attend all of the scheduled visits and evaluations
- •Macular atrophy or drusen measuring at least 125μm or multiple drusens measuring at least 63μm
- •Atrophic AMD diagnosed on OCT and by autofluorescence and OCT angiography by 2 independent experienced assessors
- •Diagnosed for less than 3 years
- •MAVC score ≥ 19 letters (Equivalent Snellen ≥ 20/400), by using a scale at an initial distance of 4m
- •For patients with secondary atrophic AMD
- •Secondary atrophic AMD, defined by persistent atrophic AMD at 1 year after the last injection of an anti-angiogenic agent, and at least 2 years after the first injection.
Exclusion Criteria
- •General criteria
- •Persons without national health insurance cover
- •Physical or mental disability ruling out participation
- •Inability to sign the written consent form, adults under guardianship
- •Any participation in a study involving an experimental drug during the previous 3 months (dietary supplements are authorised).
- •Adults under guardianship
- •General medical history
- •Uncontrolled AHT
- •Ophthalmological history
- •Severe non-proliferative or proliferative diabetic retinopathy
Outcomes
Primary Outcomes
responses to a quality of life questionnaire
Time Frame: Change compared with baseline score at month 6, month 12 and month 18
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic MaculopathyAge-Related Macular DegenerationLens, IntraocularMyopic MaculopathyNCT03882606Consorci Sanitari de Terrassa3
Completed
Not Applicable
Assessing the Quality of Life and Social Support in Age-Related Macular Degeneration PatientsAge-Related Macular DegenerationNCT05427994Asfendiyarov Kazakh National Medical University458
Recruiting
Not Applicable
Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.NCT06271330Nantes University Hospital100
Recruiting
Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationAge-Related Macular DegenerationNCT03178149Astellas Institute for Regenerative Medicine42
Terminated
Phase 2
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular DegenerationMacular DegenerationNCT00333476Genaera Corporation140